湘北威尔曼制药

Xiangbei Wellman Pharmaceutical is a prominent Chinese pharmaceutical enterprise focused on the development and production of anti-infective drugs, particularly compound antibiotics. Established in 1995, the company has built a strong reputation for its Wellman brand, specializing in beta-lactamase inhibitor combinations that combat bacterial resistance. Its core business encompasses the entire value chain from active pharmaceutical ingredient (API) synthesis to finished dosage manufacturing. Headquartered in Changsha, Hunan, the company operates several GMP-compliant facilities and maintains a robust distribution network across China. Beyond antibiotics, Wellman is also active in the cardiovascular and anti-tumor therapeutic areas. The company is recognized as a high-tech enterprise in China, consistently investing in the optimization of drug formulations.